# Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

> **NCT01758328** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** busulfan
- **DRUG:** melphalan
- **DRUG:** fludarabine
- **BIOLOGICAL:** anti-thymocyte globulin (ATG)
- **PROCEDURE:** a T cell depleted stem cell transplant

## Key facts

- **NCT ID:** NCT01758328
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2025-03-17
- **Final completion:** 2025-03-17
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01758328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01758328, "Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01758328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*